Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.49 USD
Change Today -0.009 / -1.80%
Volume 177.7K
KBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

kalobios pharmaceuticals inc (KBIO) Snapshot

Open
$0.50
Previous Close
$0.50
Day High
$0.51
Day Low
$0.46
52 Week High
07/3/14 - $2.35
52 Week Low
02/4/15 - $0.36
Market Cap
16.2M
Average Volume 10 Days
348.4K
EPS TTM
$-1.10
Shares Outstanding
33.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KALOBIOS PHARMACEUTICALS INC (KBIO)

Related News

No related news articles were found.

kalobios pharmaceuticals inc (KBIO) Related Businessweek News

No Related Businessweek News Found

kalobios pharmaceuticals inc (KBIO) Details

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.

32 Employees
Last Reported Date: 03/16/15
Founded in 2000

kalobios pharmaceuticals inc (KBIO) Top Compensated Officers

Interim Chief Executive Officer and Chief Fin...
Total Annual Compensation: $340.0K
Chief Scientific Officer
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2014.

kalobios pharmaceuticals inc (KBIO) Key Developments

KaloBios Pharmaceuticals, Inc. Appoints Ronald A. Martell to the Position of Executive Chairman

KaloBios Pharmaceuticals, Inc. announced the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. Martell currently serves as a member of the KaloBios Board of Directors. In this new role, he will work directly with the company's senior management team to refine and execute on the strategic plan to transition KaloBios to a focused monoclonal antibody company developing therapeutics for orphan oncology indications with high unmet medical need. Mr. Martell will assume the duties of Board Chairman currently held by Ted W. Love, MD, who will continue to act as lead independent director on the KaloBios Board. Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals.

Kalobios Pharmaceuticals, Inc. Proposes Series of Alternate Amendments to its Amended and Restated Certificate of Incorporation

KaloBios Pharmaceuticals, Inc. proposed a series of alternate amendments to its amended and restated certificate of incorporation, to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 4, 5, 6, 7, 8, 9 or 10 shares would be combined, converted and changed into one share of common stock, at its annual general meeting will be held on July 7, 2015.

KaloBios Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

KaloBios Pharmaceuticals, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company’s loss from operations was $9,342,000 against $10,160,000 a year ago. Net loss was $9,622,000 against $10,408,000 a year ago. Basic and diluted net loss per common share was $0.29 against $0.32 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KBIO:US $0.49 USD -0.009

KBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KBIO.
View Industry Companies
 

Industry Analysis

KBIO

Industry Average

Valuation KBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALOBIOS PHARMACEUTICALS INC, please visit www.kalobios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.